C4 THERAPEUTICS INC (CCCC) Stock Price, Quote, News and Overview
NASDAQ:CCCC - Nasdaq - US12529R1077 - Common Stock - Currency: USD
CCCC Quote, Performance and Key Statistics
1.68
+0.06 (+3.7%)
The current stock price of CCCC is 1.68 USD. In the past month the price increased by 21.74%. In the past year, price decreased by -61.64%.
CCCC Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.61 | 337.52B | ||
| AMGN | AMGEN INC | 14.22 | 158.74B | ||
| GILD | GILEAD SCIENCES INC | 14.21 | 136.81B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 116.96B | ||
| REGN | REGENERON PHARMACEUTICALS | 11.94 | 57.14B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 40.16B | ||
| ARGX | ARGENX SE - ADR | 100.5 | 35.29B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.89 | 29.17B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.62B | ||
| NTRA | NATERA INC | N/A | 22.58B | ||
| BIIB | BIOGEN INC | 8.26 | 19.14B | ||
| INSM | INSMED INC | N/A | 17.98B |
Related stock screener links
About CCCC
Company Profile
C4 Therapeutics, Inc. engages in the development of targeted protein degradation science to develop a new generation of small molecule medicines used for treating diseases. The company is headquartered in Watertown, Massachusetts and currently employs 110 full-time employees. The company went IPO on 2020-10-02. The firm is focused on delivering targeted protein degradation science to create a new generation of medicines that transform patients’ lives. The firm is focused on progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to design and optimize small-molecule medicines to address difficult-to-treat diseases. Its advanced product candidate, cemsidomide, is an orally bioavailable MonoDAC degrader of protein targets called IKZF1 and IKZF3. Cemsidomide is in clinical development for multiple myeloma (MM), and non-Hodgkin lymphoma (NHL). Its CFT1946 is an orally bioavailable BiDAC degrader designed to be potent and selective against BRAF V600X mutant proteins. The company is also developing CFT8919, an orally bioavailable, allosteric, mutant-selective BiDAC degrader of epidermal growth factor receptor (EGFR), with an L858R mutation in non-small lung cancer (NSCLC).
Company Info
C4 THERAPEUTICS INC
490 Arsenal Way, Suite 120
Watertown MASSACHUSETTS 02472 US
CEO: Andrew J. Hirsch
Employees: 110
Phone: 16172310700
C4 THERAPEUTICS INC / CCCC FAQ
What is the stock price of C4 THERAPEUTICS INC today?
The current stock price of CCCC is 1.68 USD. The price increased by 3.7% in the last trading session.
What is the ticker symbol for C4 THERAPEUTICS INC stock?
The exchange symbol of C4 THERAPEUTICS INC is CCCC and it is listed on the Nasdaq exchange.
On which exchange is CCCC stock listed?
CCCC stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for C4 THERAPEUTICS INC stock?
14 analysts have analysed CCCC and the average price target is 14.03 USD. This implies a price increase of 734.82% is expected in the next year compared to the current price of 1.68. Check the C4 THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is C4 THERAPEUTICS INC worth?
C4 THERAPEUTICS INC (CCCC) has a market capitalization of 119.30M USD. This makes CCCC a Micro Cap stock.
How many employees does C4 THERAPEUTICS INC have?
C4 THERAPEUTICS INC (CCCC) currently has 110 employees.
What are the support and resistance levels for C4 THERAPEUTICS INC (CCCC) stock?
C4 THERAPEUTICS INC (CCCC) has a support level at 1.3 and a resistance level at 1.68. Check the full technical report for a detailed analysis of CCCC support and resistance levels.
Is C4 THERAPEUTICS INC (CCCC) expected to grow?
The Revenue of C4 THERAPEUTICS INC (CCCC) is expected to decline by -40.03% in the next year. Check the estimates tab for more information on the CCCC EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy C4 THERAPEUTICS INC (CCCC) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CCCC, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CCCC, evaluating the profitability, health, valuation and growth aspects
- C4 THERAPEUTICS INC (CCCC) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- C4 THERAPEUTICS INC (CCCC) Sales and EPS estimates to see what analysts future expectations are.
- C4 THERAPEUTICS INC (CCCC) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- C4 THERAPEUTICS INC (CCCC) Insider and Institutional Ownership to learn about the owners and their transactions.
- C4 THERAPEUTICS INC (CCCC) Stock Chart to make your own analysis
- C4 THERAPEUTICS INC (CCCC) Latest news and press-releases to stay up to date.
Does C4 THERAPEUTICS INC (CCCC) stock pay dividends?
CCCC does not pay a dividend.
When does C4 THERAPEUTICS INC (CCCC) report earnings?
C4 THERAPEUTICS INC (CCCC) will report earnings on 2025-07-30.
What is the Price/Earnings (PE) ratio of C4 THERAPEUTICS INC (CCCC)?
C4 THERAPEUTICS INC (CCCC) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.47).
What is the Short Interest ratio of C4 THERAPEUTICS INC (CCCC) stock?
The outstanding short interest for C4 THERAPEUTICS INC (CCCC) is 11.16% of its float. Check the ownership tab for more information on the CCCC short interest.
CCCC Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to CCCC. When comparing the yearly performance of all stocks, CCCC is a bad performer in the overall market: 93.76% of all stocks are doing better.
CCCC Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to CCCC. The financial health of CCCC is average, but there are quite some concerns on its profitability.
CCCC Financial Highlights
Over the last trailing twelve months CCCC reported a non-GAAP Earnings per Share(EPS) of -1.47. The EPS increased by 37.71% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -32.32% | ||
| ROE | -52.92% | ||
| Debt/Equity | 0 |
CCCC Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 77% to CCCC. The Buy consensus is the average rating of analysts ratings from 14 analysts.
For the next year, analysts expect an EPS growth of -21.78% and a revenue growth -40.03% for CCCC